FILE - Packaging for AbbVie's drug, Humira, is photographed in Houston on July 18, 2014. Patients who take the autoimmune disease treatment may see some price relief when several lower-cost ...

Investors certainly are. It has now been several months since a copycat version of the arthritis therapy Humira—the highest-grossing drug ever—was launched. For now, doctors are still mostly ...

Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s (ABBV.N), opens new tab blockbuster arthritis drug Humira this year, but the cost savings are ...

An illustration of the packaging for Amgen Inc's Amjevita as well as the 40 milligram auto injector containing a bio similar version of AbbVie's Inc's Humira ...

Sales of AbbVie’s blockbuster drug Humira peaked at $18.9bn last year and, according to analysts at Evaluate Pharma, the product is expected to generate $15.2bn through to 2024. These figures ...

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor. Starting July 1, alternatives ...

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July. But lower ...

AbbVie's 132 patents related to Humira do not violate antitrust law, U.S. Circuit Judge Frank Easterbrook said Monday, rejecting claims that the patents wrongly kept generic competitors out of the ...

In a significant victory for AbbVie, a U.S. appeals court panel declined to revive a lawsuit that accused the company of using a so-called patent thicket to forestall competition for its Humira ...

Seven new alternatives to the high-cost Humira drug will be available in July. Some will be offered at significantly lower prices, but will patients see big savings? Lowering drug prices for ...